Concepedia

Eyal Meiri

EM

Statistics

Publications

6

Citations

366

H-Index

6

Active since

2007

Affiliations

Cancer Treatment Centers of America(Current)

Duke Medical Center

The University of Texas Southwestern Medical Center

American Society of Clinical Oncology

Eyal Meiri is an author at Cancer Treatment Centers of America specializing in medicine, oncology, and oncology pharmacotherapy.

Publications per year

2007–2020

6

Publications

6

Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting

Eyal Meiri, Haresh Jhangiani, James J. Vredenburgh et al. · Current Medical Research and Opinion · 2007 · 213 citations

, , +17

Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Eyal Meiri, Elizabeth Garrett‐Mayer, Susan Halabi et al. · Journal of Clinical Oncology · 2020 · 53 citations

, , +17

Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with <i>ERBB2</i> amplification or overexpression: Results from the TAPUR Study.

R. Gupta, Elizabeth Garrett‐Mayer, Susan Halabi et al. · Journal of Clinical Oncology · 2020 · 41 citations

, , +14

Clinical activity of avapritinib in ≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST).

Michael C. Heinrich, Robin L. Jones, Margaret von Mehren et al. · Journal of Clinical Oncology · 2019 · 24 citations

, , +17

Phase 2 study of talabostat/gemcitabine in Stage IV pancreatic cancer

F. Warren Nugent, Charles Cunningham, Minal Barve et al. · Journal of Clinical Oncology · 2007 · 21 citations

, , +15

1–5 of 6